Skip to main content

Table 1 Patient characteristics

From: Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

Characteristics Data
Total number of patients 190
Age, yr 51 (18–84)
Menopausal status  
 Premenopausal 87 (46 %)
 Perimenopausal 24 (13 %)
 Postmenopausal 79 (42 %)
Histologic findings  
 Ductal 140 (74 %)
 Lobular 22 (12 %)
 Other 24 (13 %)
 Unknown 4 (2 %)
Tumor grading  
 G1 13 (7 %)
 G2 85 (45 %)
 G3 88 (46 %)
 Unknown 4 (2 %)
Tumor size before NACT  
 cT1a–cT1c 46 (24 %)
 cT2 111 (58 %)
 Above cT2 29 (15 %)
 Unknown 4 (2 %)
Tumor size after NACT  
 ypT0(is) 46/177 (26 %)
 ypT1a–ypT1c 71/177 (40 %)
 ypT2 47/177 (27 %)
 Above ypT2 13/177 (7 %)
 Unknown 13/190
Nodal status before NACT  
 cN0 94 (49 %)
 cN1 83 (44 %)
 cN2, cN3 10 (5 %)
 Unknown 3 (2 %)
Nodal status after NACT  
 yN0 116/180 (64 %)
 yN1 48/180 (27 %)
 yN2,N3 16/180 (9 %)
 Unknown 10/190
Estrogen receptor  
 Positive 131 (69 %)
 Negative 58 (31 %)
 Unknown 1 (1 %)
Progesterone receptor  
 Positive 116 (61 %)
 Negative 73 (38 %)
 Unknown 1 (1 %)
HER2 status  
 Positive 56 (29 %)
 Negative 133 (70 %)
 Unknown 1 (1 %)
Tumor subtype (IHC)  
 ER−, PR−, HER2− 36 (19 %)
 ER−, PR−, HER2+ 15 (8 %)
 ER+/PR+, HER2− 97 (51 %)
 ER+, PR+, HER2+ 41 (22 %)
 Unknown/n.a. 1 (1 %)
Pathological response  
 Complete response 37/176 (21 %)
 Partial response 127/176 (72 %)
 No response 12/176 (7 %)
 Unknown 14 (7 %)
DTC positive  
 Before therapy 38/142 (27 %)
 After therapy 33/165 (20 %)
CTC positive  
 Before therapy 32/135 (24 %)
 After therapy 11/133 (8 %)
slCTC positive  
 Before therapy 46/91 (51 %)
 After therapy 18/90 (20 %)
DTC and/or CTC positive  
 Before therapy 59/136 (43 %)
 After therapy 44/140 (34 %)
DTC and/or slCTC-pos.  
 Before therapy 74/107 (69 %)
 After therapy 48/103 (47 %)
CTC and/or slCTC positive  
 Before therapy 57/92 (62 %)
 After therapy 25/89 (28 %)
Survival  
 OS 54 mo (2–93 mo)
 Alive 169 (89 %)
 Dead 19 (10 %)
 Unknown 2 (1 %)
 PFS 52 mo (2–93 mo)
Recurrence  
 Alive without relapse 135 (71 %)
 Relapse 22 (12 %)
 Unknown 33 (17 %)
  1. CTC circulating tumor cell, DTC disseminated tumor cell, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IHC immunhistochemstry, NACT neoadjuvant chemotherapy, OS overall survival, PFS progression-free survival, PR progesterone receptor, slCTC stem cell–like circulating tumor cell
  2. Data are presented as median (range) or number (%)